BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Everest Medicines Secures Hong Kong Approval for VELSIPITY® in Ulcerative Colitis

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeu...

April 30, 2025 | News

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Akeso Secures NMPA Approval for Ebdarokimab in Moderate-to-Severe Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, ...

April 21, 2025 | News

Belief BioMed and Takeda China Announce NMPA Approval of China’s First Gene Therapy for Hemophilia B

Belief BioMed ("BBM") and Takeda China jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has be...

April 11, 2025 | News

Lucence and HKPOS Launch Hong Kong’s First Study on Blood Test for Early Lung Cancer Detection

In a two-year collaboration with HKPOS, 600 lung cancer patients aged 45-74 in Hong Kong will be studied using Lucence's non-invasive liquid biopsy to as...

April 10, 2025 | News

China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the se...

April 08, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

China’s AIM Vaccine Gets FDA Nod for mRNA Shingles Vaccine Trial

AIM Vaccine Co., developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). As o...

March 25, 2025 | News

Teva Hong Kong Partners with Kerry Pharma to Enhance Medicine Distribution Across Hong Kong, Macau, and the Greater Bay Area

Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Ke...

March 17, 2025 | News

Everest Medicines Secures Hong Kong Approval for VELSIPITY® in Ulcerative Colitis

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso Secures NMPA Approval for Ebdarokimab in Moderate-to-Severe Plaque Psoriasis

Belief BioMed and Takeda China Announce NMPA Approval of China’s First Gene Therapy for Hemophilia B

Lucence and HKPOS Launch Hong Kong’s First Study on Blood Test for Early Lung Cancer Detection

China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

China’s AIM Vaccine Gets FDA Nod for mRNA Shingles Vaccine Trial

Teva Hong Kong Partners with Kerry Pharma to Enhance Medicine Distribution Across Hong Kong, Macau, and the Greater Bay Area

Ascletis’ ASC47 Shows Promise as a Long-Acting, Muscle-Preserving Obesity Treatment in Phase Ib Study

AIM Vaccine Secures Production License for World’s First Serum-Free Rabies Vaccine

Gleneagles Hospital Hong Kong Becomes Asia’s First Private Hospital to Offer Histotripsy for Liver Cancer Treatment

AIM Vaccine Secures Clinical Approval for Next-Gen Diploid Rabies Vaccine, Marking a Major Technological Leap

Akeso Completes Patient Enrollment for Phase III Trial of Cadonilimab as Adjuvant Therapy for Hepatocellular Carcinoma

Stay Connected